Stocktoria
Alaunos Therapeutics, Inc. TCRT
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-08-20
Alaunos Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 | $0 | — | $146,000 | $15.9M | $6.9M |
| R&D expense | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M | $52.7M | $38.3M | $34.1M | $45.1M | $157.8M |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M | -$77.5M | -$80.4M | -$57.9M | -$53.9M | -$53.5M | -$165.3M |
| Interest expense | — | — | $1.9M | $3.2M | $1.2M | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — | — | — |
| Net income | -$4.2M | -$4.7M | -$4.7M | -$37.7M | -$78.8M | -$80.0M | -$117.8M | -$53.1M | -$54.3M | -$165.3M |
| EPS (diluted) | $-2.20 | $-2.92 | $-21.97 | $-2.61 | $-0.37 | $-0.38 | $-0.70 | $0.96 | $-0.53 | $-1.32 |
| Operating cash flow | -$2.9M | -$5.0M | -$30.1M | -$29.2M | -$61.5M | -$57.0M | -$40.9M | -$49.5M | -$54.7M | -$58.3M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M | -$64.8M | -$66.8M | -$41.1M | -$49.9M | -$55.4M | -$58.9M |
| Cash & equivalents | $1.4M | $1.1M | $6.1M | $39.1M | $76.1M | $115.1M | $79.7M | $61.7M | $70.9M | $81.1M |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M | $94.9M | $146.3M | $109.1M | $95.1M | $105.6M | $106.3M |
| Total liabilities | $813,000 | $692,000 | $2.0M | $26.4M | $36.8M | $22.4M | $14.1M | $9.5M | $58.4M | $58.3M |
| Shareholders' equity | $2.2M | $2.1M | $6.3M | $38.6M | $58.1M | $124.0M | $95.0M | $85.6M | -$96.8M | -$77.3M |
Growth · year-over-year · Revenue CAGR -59.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -50.0% | +100.0% | -99.8% | +634.2% | — | — | — | -99.1% | +131.7% | — |
| EPS growth | — | — | — | — | — | — | -172.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.